AI Article Synopsis
- Metformin is the primary medication for treating insulin resistance in PCOS and has been extensively researched, while inositols have recently gained attention but lack strong evidence.
- A study analyzed 6 randomized control trials involving 388 women with PCOS to compare the effects of combined metformin and inositols against metformin alone.
- Results showed that the combination therapy improved menstrual cycle regularity and reduced certain hormone ratios, but no significant differences were found in acne, body weight, blood sugar, or insulin resistance measures; more research is needed on inositol's effectiveness.
Article Abstract
Purpose: Metformin was the first medication targeting insulin resistance in PCOS, and it has been extensively studied as a metabolic treatment option. In recent years, inositols have emerged as potential treatment options for PCOS, but confidence in the available evidence supporting their use is limited.
Methods: We comprehensively searched PubMed, Embase, and Cochrane databases for RCTs comparing the use of combined metformin and inositol versus metformin alone in women with PCOS. A random-effects model was used to calculate the risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). A p-value of <0.05 was deemed as statistically significant.
Results: Six RCTs and 388 patients were included in the analysis, with follow-up ranging from 3 to 6 months. Combination therapy was significantly associated with improved menstrual cycle regularity (RR 1.56; 95% CI 1.01 to 2.41; p = 0.04), and lower values of modified Ferriman-Gallwey score (MD -0.97; 95% CI -1.53 to -0.40; p < 0.01) and LH/FSH ratios (MD -0.13; 95% CI -0.24 to -0.03; p = 0.01). Differences in acne (p = 0.58), body mass index (p = 0.13), fasting blood glucose (p = 0.07) and HOMA-IR (p = 0.25) were not statistically significant.
Conclusion: In this meta-analysis of RCTs, combination therapy was associated with cycle regularization and reduction in hirsutism and LH/FSH ratio compared to metformin monotherapy. Further studies are needed to clarify the true benefits of the use of inositol in PCOS treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12020-024-04052-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Phase III, Double-Blind, Randomized, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Metformin Hydrochloride and Myo-Inositol Compared to Metformin in Patients With Polycystic Ovary Syndrome.
Cureus
December 2024
Department of Medical Affairs, Eris Lifesciences Ltd., Ahmedabad, IND.
Background Polycystic ovary syndrome (PCOS) poses a significant health concern among reproductive-aged women and is characterized by ovarian dysfunction, hyperandrogenism, and insulin resistance. This study aims to assess the efficacy and safety of metformin and myo-inositol combination therapy compared to metformin monotherapy in patients with PCOS. Materials and methods This was a phase III, double-blind, randomized controlled clinical trial.
View Article and Find Full Text PDFComparative efficacy and safety of metformin, anti-obesity agents, and myoinositol in improving IVF/ICSI outcomes and reducing ovarian hyperstimulation syndrome in women with polycystic ovary syndrome: a systematic review and network meta-analysis.
J Ovarian Res
December 2024
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Purpose: To compare the efficacy and safety of metformin, anti-obesity agents, and inositol with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
Methods: A comprehensive search was conducted in PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov for studies published in English up to October 26, 2024.
Metformin ameliorates vanadium pentoxide or gamma irradiation-stimulated hepatotoxicity in male rats via targeting endoplasmic reticulum stress-induced apoptosis.
Hum Exp Toxicol
December 2024
Drug Radiation Research Department, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt.
Introduction: This work aims to validate the ameliorative influence of metformin against endoplasmic reticulum stress (ERS)-prompted apoptosis caused by vanadium pentoxide (VO) or gamma-irradiation (γ-irradiation) in hepatic tissues of male rats.
Methods: There were six groups of rats: the control, metformin (100 mg/kg body weight, .), VO (12.
Causal relationship between fertility nutrients supplementation and PCOS risk: a Mendelian randomization study.
Front Endocrinol (Lausanne)
October 2024
Department of Histology and Embryology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China.
Article Synopsis
- Polycystic ovary syndrome (PCOS) is a common condition among reproductive-age women, with few effective treatment options; research suggests fertility nutrient supplements might help, but their influence on PCOS risk is unclear.
- This study used Mendelian Randomization to analyze 10 specific fertility nutrients, including omega-3 fatty acids and curcumin, to determine their causal effect on PCOS risk.
- Results showed that omega-3 fatty acids can reduce PCOS risk while betaine increases it; certain nutrients like berberine and curcumin also demonstrated potential protective roles against PCOS.
Polycystic ovary syndrome and type 1 diabetes - the current state of knowledge.
Endokrynol Pol
October 2024
Department of Internal Medicine, Diabetology and Nephrology in Zabrze, Medical University of Silesia, Katowice, Poland.
Article Synopsis
- Type 1 diabetes mellitus (T1DM) and polycystic ovary syndrome (PCOS) are interconnected conditions that can worsen metabolic health and raise cardiovascular risks, significantly impacting patients' quality of life.
- Recommended treatment includes lifestyle changes like increased physical activity and weight loss, alongside pharmacological options such as metformin and GLP-1 receptor agonists.
- Emerging treatments and supplements, such as anti-androgens and dietary components, plus the gut microbiome's role, are areas of interest for improving symptoms and metabolic control in patients with both T1DM and PCOS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!